Castration-Synchronized Upfront Docetaxel for metastatic Hormone Sensitive Prostate Cancer considering Epithelial to Mesenchymal Transition

Main Article Content

Teiichiro Aoyagi Isao Kuroda

Abstract

Upfront docetaxel therapy for metastatic hormone sensitive prostate cancer (mHSPC) has been reported to be improved outcome, although the best timing to start decetaxel and/or the duration of chemotherapy have not been cleared. We consider epithelial to mesenchymal transition (EMT) at the beginning of the hormonal therapy would be the mechanism to obtain apoptosis tolerance of prostatic cells. For localized prostate cancer, we used LH-RH antagonist (degarelix) twice and performed high-intensity focused ultrasound therapy (HIFU) after two weeks of the first degarelix, the timing of inducing EMT. This regimen apparently improved HIFU results. So for mHSPC, we started two to three courses of upfront docetaxel synchronously the beginning of the androgen deprivation therapy (ADT). Of 38 mHSPC patients underwent upfront docetaxel with our protocol, 18 patients maintained low prostate specific antigen value less than 0.1 ng/ml for more than two years without adding new androgen axis targeted therapy agents (ARAT). Although recent study suggests all mHSPC patients should receive systemic triple therapy including ADT, docetaxel and ARAT, our study indicated that upfront docetaxel use considering EMT may select the patients requiring triple therapy, and reduce a burden both for the patients and medical economy.

Article Details

How to Cite
AOYAGI, Teiichiro; KURODA, Isao. Castration-Synchronized Upfront Docetaxel for metastatic Hormone Sensitive Prostate Cancer considering Epithelial to Mesenchymal Transition. Medical Research Archives, [S.l.], v. 10, n. 10, oct. 2022. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/3235>. Date accessed: 06 dec. 2022. doi: https://doi.org/10.18103/mra.v10i10.3235.
Section
Research Articles

References

1. Gravis G, Fizzazi K, Joly F, Oudard S, et al . Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): A Randomized, Open-Label, Phase 3 Trial. Lancet Oncol. 2013;14: 149-158. https://doi.org/10.1016/S1470-2045(12)70560-0
2. Sweeney CJ, Chen YH, Carducci M, Liu G, et al . Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. NEJM. 2015;373: 737-746. https://doi.org/10.1056/NEJMoa1503747
3. James ND, Sydes MR, Mason MD, et al . Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE (NCT00268476). J Clin Oncol. 2015;33: 5001. https://doi.org/10.1200/jco.2015.33.15_suppl.5001
4. Mottet N, van den Bergh RCN, Briers E, et al . EAU-ESTROESUR-SIOG guidelines on prostate cancer. 2018;6.4.5.2 ADT combined with chemotherapy. 70. https://uroweb.org/wp-content/uploads/EAU-ESUR-ESTRO-SIOG-Guidelines-on-Prostate-Cancer-large-text-V2.pdf
5. Fizazi K, Foulon S, Carles J, et al. PEACE-1 investigators. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet 2022; Apr 30; 399(10336):1695-1707. doi: 10.1016/S0140-6736(22)00367-1. Epub 2022 Apr 8.
6. Gravis G, Audenet F, Irani J, et al. Chemotherapy in hormone sensitive metastatic prostate cancer: Evidences and uncertainties from the literature. Cancer Treat Rev. 2017; 55: 211-217. https://doi.org/10.1016/j.ctrv.2016.09.008
7. Eigl BJC, Eggener SE, Baybik J, Ettinger S, Chi KN, Nelson C, et al . Timing Is Everything: Preclinical Evidence Supporting Simultaneous Rather than Sequential Chemohormonal Therapy. Clin Cancer Res. 2005;11: 4905-4911. https://doi.org/10.1158/1078-0432.CCR-04-2140
8. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer. 1993; 71: 2782-2790. https://doi.org/10.1002/1097-0142(19930501)71:9<2782::AID-CNCR2820710916>3.0.CO;2-Z
9. Sun Y, Wang BE, Leong KG, et al. Androgen deprivation causes epithelial–mesenchymal transition in the prostate: Implications for androgen-deprivation therapy. Cancer Res. 2011; 72(2): 527–36. doi: 10.1158/0008-5472.CAN-11-3004
10. Li P, Yang R, Gao WQ. Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer. Mol Cancer. 2014; 13:55 http://www.molecular-cancer.com/content/13/1/55
11. Aoyagi T, Takizawa I, Kuroda I. Basal cell proliferation induced by chlormadinone acetate suggests stem cell transformation of prostatic cells. J Cancer Ther. 2018; 9: 268-273. https://doi.org/10.4236/jct.2018.93024
12. Toivanen R, Mohan A, Shen MM. Basal progenitors contribute to repair of the prostate epithelium following induced luminal anoikis. Stem Cell Reports. 2016; 6: 660-667. http://dx.doi.org/10.1016/j.stemcr.2016.03.007
13. Jaworska D, Szliska E. Targeting apoptotic activity against prostate cancer stem cells. Int J Mol Sci. 2017; 18: 1648. doi:10.3390/ijms18081648
14. Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Kyprianou N. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 2010; 70(20): 7992–8002. DOI: 10.1158/0008-5472.CAN-10-0585
15. Martin SK, Kamelgarn M, Kyprianou N. Cytoskeleton targeting value in prostate cancer treatment. Am J Clin Exp Urol 2014;2(1):15-26 /ISSN:2330-1910/AJCEU0000332
16. Blana S, Brown SCW, Chaussy C, Conti GN, Eastham JA, Ganzer R, et al. High-intensity focused ultrasound for prostate cancer: Comparative definitions of biochemical failure. BJU Int. 2009; 104: 1058-1062. http://dx.doi.org/10.1111/j.1464-410X.2009.08518.x
17. Aoyagi T, Kuroda I. Enhancement of HIFU effect by simultaneous short course degarelix for early stage prostate cancer: A pilot study. Open Journal of Urology. 2016; 6: 49-54 http://dx.doi.org/10.4236/oju.2016.63010
18. Klotz L, Boccon-Gibod L, Shore N, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in prostate cancer patients. BJU Int. 2008; 102: 1531–1538. doi: 10.1111/j.1464-410X.2008.08183.x.
19. Aoyagi T, Kuroda I, Nagao G. Upfront docetaxel with LH-RH antagonist for metastatic hormone sensitive prostate cancer considering epithelial to mesenchymal transition. Open Journal of Urology. 2020; 10: 284-292. https://doi.org/10.4236/oju.2020.1011033
20. Fizazi K, Jenkins C, Tannock IF. Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. Ann of Oncol. 2015; 26: 1660-1667. https://doi.org/10.1093/annonc/mdv245
21. Isaksson J, Green H, Papantoniou D, et al. Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer. 2021; World J Clin Oncol. 24(12): 1009-1022. DOI: 10.5306/wjco.v12.i11.1009
22. Ahmed M, Li LC. Adaptation and clonal selection models of castration-resistant prostate cancer: current perspective. Int J Uol. 2013; 20: 362-371. https://doi.org/10.1111/iju.12005
23. Thomas C, Baunacke M, Erb HHH, et al. Systemic triple therapy in metastatic hormone-sensitive prostate cancer (mHSPC): Ready for prime time or still to be explored? Cancers 2021; 14: 8. https://doi.org/10.3390/cancers14010008